Ardelyx (ARDX) CMO details 301,000 options at $6.11 and 201,000 shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ARDELYX, INC. Chief Medical Officer Dinavahi Rajani reported her equity holdings in connection with a Form 3 filing. She holds stock options to purchase 301,000 shares of Common Stock at an exercise price of $6.11 per share, expiring on April 1, 2036.
She also directly holds 201,000 shares of Common Stock. The option grant vests over time, with 25% of the shares vesting on April 1, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to her continued employment or service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Dinavahi Rajani
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 301,000 shares (Direct);
Common Stock — 201,000 shares (Direct)
Footnotes (1)
- Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. Twenty Five Percent (25%) of the shares subject to the option vest on April 1, 2027 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Key Figures
Option exercise price: $6.11 per share
Underlying option shares: 301,000 shares
Common Stock held: 201,000 shares
+3 more
6 metrics
Option exercise price
$6.11 per share
Stock Option (Right to Buy) on Common Stock
Underlying option shares
301,000 shares
Common Stock underlying stock options, direct ownership type
Common Stock held
201,000 shares
Total Common Stock directly held following reported holdings
Option expiration
April 1, 2036
Expiration date of reported stock options
Initial option vesting
25% on April 1, 2027
First tranche of stock option vesting
Remaining vesting schedule
36 monthly installments
Post-2027 vesting for remaining option shares
Key Terms
Restricted stock units ("RSUs"), Stock Option (Right to Buy, vesting, Common Stock
4 terms
Restricted stock units ("RSUs") financial
"Restricted stock units ("RSUs"). The Reporting Person is entitled"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)"
vesting financial
"subject to the option vest on April 1, 2027 and the remaining shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
How many ARDELYX (ARDX) stock options does the CMO hold and at what price?
The Chief Medical Officer holds stock options on 301,000 shares of ARDELYX Common Stock with an exercise price of $6.11 per share. These options represent the right to buy shares at that fixed price before the stated expiration date.
When do the ARDELYX (ARDX) stock options held by the CMO expire?
The reported stock option position expires on April 1, 2036. This long-dated expiration gives the Chief Medical Officer an extended window to exercise the options, subject to the vesting schedule and her continued employment or service with ARDELYX.
What is the vesting schedule for the ARDELYX (ARDX) stock options?
According to the filing, 25% of the option shares vest on April 1, 2027. The remaining shares then vest in 36 successive, equal monthly installments, conditioned on the Chief Medical Officer’s continued employment or service with ARDELYX on each vesting date.
What does the RSU footnote in the ARDELYX (ARDX) Form 3 indicate?
The footnote explains that restricted stock units (RSUs) entitle the reporting person to receive one share of Common Stock for each RSU upon vesting. It clarifies the basic RSU-to-share conversion but does not specify the total RSU count in this excerpt.